Ohio Consortium Clinical Center for the NHLBI Prevention and Early Treatment of A

描述（由申请人提供）：NHLBI赞助的急性肺损伤预防和早期治疗（PETAL）临床试验网络的目的是组成一个临床中心（CC）网络，与临床协调中心（CCC）合作，开发和开展随机对照临床试验，以预防或治疗和/或改善患有急性肺损伤（ALI）或急性呼吸窘迫的患者或有风险的患者的结果

DESCRIPTION (provided by applicant): The purpose of the NHLBI sponsored Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network is to constitute a network of Clinical Centers (CC) to collaborate with the Clinical Coordinating Center (CCC) to develop and conduct randomized controlled clinical trials to prevent or treat, and/or improve the outcome of patients with, or who are at risk for, Acute Lung Injury (ALI) or the Acute Respiratory Distress Syndrome (ARDS). Studies conducted by this Network are expected to emphasize prevention, early treatment and multidisciplinary approaches. The Network will consist of approximately eleven Clinical Centers (CCs) and a Clinical Coordinating Center (CCC). Each CC will have two principal investigators, one representing pulmonary and/or critical care medicine and the other representing a specialty with early access to patients at risk for lung injury, such as emergency medicine. Each CC must consist of a primary hospital and at least one other hospital. Each CC will be expected to enroll a minimum of 40 subjects per year for 5.5 years. The "Ohio Consortium Clinical Center" will consist of four major medical institutions in the state of Ohio: Cleveland Clinic, The Ohio State University in Columbus, University of Cincinnati and Summa Health System in Akron. These institutions all treat a large number of critically ill patients, and the investigators and research coordinators of the Ohio Consortium Clinical Center are experienced in the treatment of patients with ALI, and patients at-risk to develop ALI. The personnel of the Ohio Consortium Clinical Center includes two physicians who have served as Clinical Center PIs for the NHLBI sponsored ARDS Clinical Trial Network and two other physicians who have served as site PIs in the NHLBI sponsored multi-center "ProCESS" trial - (Protocolized Care for Early Septic Shock). The Ohio Consortium Clinical Center proposes two clinical trials: 1)Keratinocyte Growth Factor (KGF) for The Prevention or Treatment of Early ALI Due to Infectious Pneumonia and 2) Zinc supplementation for Acute Lung Injury Prevention (ZAP Trial).